SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Emergency services search for five people last seen in missing Jeep - 2Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
- 3Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
- 4Ariana Grande to host 'Saturday Night Live' Christmas show with Cher as musical guest, returning after nearly 40 years
- 5Exclusive-Head of Pemex's production arm to step down in coming days, sources say
- Wellness Bits of knowledge Readily available: A Survey of \Following Wellbeing and Progress\ Wellness Wearables
- The race is on to turn your body into a GLP-1 factory
- Scientists reveal earliest evidence for shifting of Earth’s crust
- NASA Perseverance rover sees megaripples on Mars | Space photo of the day for Jan. 7, 2026.
- Instructions to Augment the Presentation of Your Kona SUV
- 10 Energizing Vocations in the Innovation Business
- Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- Artemis 2 astronauts — now halfway to the moon — report 'burning smell' from toilet, but everything's fine
- As nations push for more ambition at climate talks, chairman says they may get it
